Search

Very low-dose radiotherapy (VLDRT) is effective for treating grade 3A follicular lymphoma and provides patients with a shorter treatment course and fewer side effects.

… Friday, March 6, 2020 Very low-dose radiotherapy (VLDRT) is effective for treating grade 3A follicular lymphoma and provides patients with a shorter treatment course and fewer side effects. We observed outstanding radiographic responses, local control, and associated palliative benefits in our recent

Dr. Deb Schrag, Chair of the Department of Medicine, and Dr. Lorenz Studer, Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center (MSK), have been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.

… Monday, October 21, 2024 Dr. Deb Schrag, Chair of the Department of Medicine, and Dr. Lorenz Studer, Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center (MSK), have been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists

Learn about some of the most important advances in cancer treatment and clinical trials at MSK in 2024.

… Tuesday, December 17, 2024 Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in a variety of cancer treatments in 2024 — including new surgical techniques, innovative cancer vaccines, drugs to boost radiation therapy’s effectiveness, and novel tools to diagnose and detect cancer

Memorial Sloan Kettering Cancer Center (MSK) molecular pharmacologist Daniel Heller, PhD, and colleagues have identified a new strategy to target drugs specifically to cancer sites, including metastatic tumors. The approach involves nanoparticles designed to mimic a mechanism that tumors themselves use to metastasize throughout the body. This work, which will be featured on the cover of the June 29 issue of Science Translational Medicine, was applicable across a wide range of tumor and drug types and can potentially be applied to other conditions including vascular and autoimmune diseases.

… Wednesday, June 29, 2016 Memorial Sloan Kettering Cancer Center (MSK) molecular pharmacologist Daniel Heller, PhD, and colleagues have identified a new strategy to target drugs specifically to cancer sites, including metastatic tumors. The approach involves nanoparticles designed to mimic a mechanism

A recent study found that the cell lines most commonly used for research on ovarian cancer are not the most suitable.

… Monday, August 26, 2013 Summary A recent study found that the cell lines most commonly used for research on ovarian cancer are not the most suitable. Research done in cancer cell lines – colonies of cells that derive from a patient’s tumor and can be grown in culture indefinitely – has revealed important

The U.S. Food and Drug Administration (FDA) approved 11 cancer drugs in 2024 based on significant contributions from MSK researchers.

… Friday, June 6, 2025 In 2024, the U.S. Food and Drug Administration (FDA) approved 11 drugs based on clinical trials in which MSK played a pivotal role.  These approvals expand treatment options for a range of cancers, including subtypes of brain, lung, breast, thyroid, and colorectal cancer, and span

Pediatric oncologist Julia Glade Bender talks about the challenges of treating rare childhood cancers and how personalized medicine is leading to better therapies for tumors that are especially hard to treat.

… Friday, September 20, 2019 Summary In this Q & A, pediatric oncologist Julia Glade Bender talks about how childhood cancers and adult cancers are different, and the promise of personalized medicine to treat tumors that are especially challenging. Julia Glade Bender is a pediatric oncologist and Vice

Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center (MSK) Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty. The studies were presented this week at the San Antonio Breast Cancer Symposium.

… Friday, December 11, 2015 Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center

Meet Andrew Kung, MSK’s new Chair of the Department of Pediatrics.

… Thursday, September 15, 2016 Summary Andrew Kung has a long history of caring for children with cancer. He now brings his talents to MSK as the new Chair of the Department of Pediatrics . Andrew Kung understands the first-day-of-school excitement that many of his patients went through this month — because

The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan Kettering Cancer Center is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers.

… Monday, February 11, 2008 The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) is the first prospective examination of